

## Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. *N Engl J Med* 2007;356:551-66.

**SUPPLEMENTAL TABLE 1.** Treatment Results by Treatment Group Stratified by BMI.

BMI < 30 (N=179)			BMI 30-34 (N=135)			BMI ≥ 35 (N=311)			
	Clomiphene Citrate (n=57)	Metformin XR (n=57)	Combined Clomiphene and Metformin (n=65)	Clomiphene Citrate (n=42)	Metformin XR (n=45)	Combined Clomiphene And Metformin (n=48)	Clomiphene Citrate (n=110)	Metformin XR (n=105)	Combined Clomiphene And Metformin (n=96)
Mean (SD) BMI	25.2 (3.2)	25.3 (3.2)	24.6 (3.3)	32.6 (1.4)	32.4 (1.3)	32.5 (1.6)	42.8 (6.0)	42.6 (5.2)	41.5 (5.3)
Ovulation	135/222 (60.8%)	100/261 (38.3%)	219/300 (73.0%)	103/173 (59.5%)	99/225 (44.0%)	134/222 (60.4%)	224/547 (41.0%)	97/530 (18.3%)	229/442 (51.8%)
Conception	24/57 (42.1%)	12/57 (21.1%)	30/65 (46.2%)	12/42 (28.6%)	8/45 (17.8%)	16/48 (33.3%)	26/110 (23.6%)	5/105 (4.8%)	34/96 (35.4%)
Pregnancy	21/57 (36.8%)	7/57 (12.3%)	26/65 (40.0%)	8/42 (19.0%)	7/45 (15.6%)	10/48 (20.8%)	21/110 (19.1%)	4/105 (3.8%)	29/96 (30.2%)
Singleton	19/21 (90.5%)	7/7 (100.0%)	25/26 (96.2%)	8/8 (100.0%)	7/7 (100.0%)	9/10 (90.0%)	20/21 (95.2%)	4/4 (100.0%)	29/29 (100.0%)
Twins	1/21 (4.8%)	0	1/26 (3.8%)	0	0	1/10 (10.0%)	1/21 (4.8%)	0	0
Triplets	1/21 (4.8%)	0	0	0	0	0	0	0	0
Other	0	0	0	0	0	0	0	0	0
Live Birth	21/57 (36.8%)	5/57 (8.8%)	24/65 (36.9%)	8/42 (19.0%)	6/45 (13.3%)	10/48 (20.8%)	18/110 (16.4%)	4/105 (3.8%)	22/96 (22.9%)
All pregnancy loss among patients who conceived	4/24 (16.7%)	7/12 (58.3%)	6/30 (20.0%)	4/12 (33.3%)	2/8 (25.0%)	6/16 (37.5%)	8/26 (30.1%)	1/5 (20.0%)	12/34 (35.3%)
1 <sup>st</sup> trimester loss	3/24 (12.5%)	7/12 (58.3%)	4/30 (13.3%)	4/12 (33.3%)	2/8 (25.0%)	6/16 (37.5%)	7/26 (26.9%)	1/5 (20.0%)	10/34 (29.4%)
Biochemical or no fetal heart beat	1/24 (4.2%)	5/12 (41.7%)	4/30 (13.3%)	4/12 (33.3%)	1/8 (12.5%)	5/16 (31.3%)	5/26 (19.2%)	1/5 (20.0%)	4/34 (11.8%)
Ectopic	2/24 (8.3%)	0/12 (0.0%)	0/30 (0.0%)	0/12 (0.0%)	0/8 (0.0%)	1/16 (6.3%)	0/26 (0.0%)	0/5 (0.0%)	1/34 (2.9%)
Loss after observed heart beat	0/24 (0.0%)	2/12 (16.7%)	0/30 (0.0%)	0/12 (0.0%)	1/8 (12.5%)	0/16 (0.0%)	2/26 (7.7%)	0/5 (0.0%)	5/34 (14.7)
2 <sup>nd</sup> -3 <sup>rd</sup> trimester loss	1/24 (4.2%)	0/12 (0.0%)	2/30 (6.7%)	0/12 (0.0%)	0/8 (0.0%)	0/16 (0.0%)	1/26 (3.8%)	0/5 (0.0%)	2/34 (5.9%)

Ovulation was defined by a serum progesterone level > 5 ng/mL; Conception was defined as any positive serum hCG level; Pregnancy defined as an intrauterine pregnancy with fetal heart motion as determined by transvaginal ultrasound; and Live Birth defined as delivery of any viable infant.

**SUPPLEMENTAL TABLE 2.** Results by Treatment Group Stratified by Previous Therapy.

	Previous Therapy (N=343)			No Previous Therapy (N=283)		
	Clomiphene Citrate (n=116)	Metformin XR (n=111)	Combined Clomiphene and Metformin (n=116)	Clomiphene Citrate (n=93)	Metformin XR (n=97)	Combined Clomiphene and Metformin (n=93)
Ovulation	272/538 (50.6%)	151/554 (27.3%)	334/559 (59.7%)	190/404 (47.0%)	145/465 (31.2%)	248/405 (61.2%)
Conception	32/116 (27.6%)	13/111 (11.7%)	39/116 (33.6%)	30/93 (32.3%)	12/97 (12.4%)	41/93 (44.1%)
Pregnancy	24/116 (20.7%)	8/111 (7.2%)	31/116 (26.7%)	26/93 (28.0%)	10/97 (10.3%)	34/93 (36.6%)
Singleton	24/24 (100.0%)	8/8 (100.0%)	30/31 (96.8%)	23/26 (88.5%)	10/10 (100.0%)	33/34 (97.1%)
Twins	0	0	1/31 (3.2%)	2/26 (7.7%)	0	1/34 (2.9%)
Triplets	0	0	0	1/26 (3.8%)	0	0
Other	0	0	0	0	0	0
Live Births	23/116 (19.8%)	6/111 (5.4%)	26/116 (22.4%)	24/93 (25.8%)	9/97 (9.3%)	30/93 (32.3%)
All pregnancy loss among patients who conceived	9/32 (28.1%)	7/13 (53.9%)	13/39 (33.3%)	7/30 (23.3%)	3/12 (25.0%)	11/41 (26.8%)
1 <sup>st</sup> trimester loss	9/32 (28.1%)	7/13 (53.9%)	11/39 (28.2%)	5/30 (16.7%)	3/12 (25.0%)	9/41 (22.0%)
Biochemical or no fetal heart beat	6/31 (18.8%)	5/13 (38.5%)	8/39 (20.5%)	4/30 (13.3%)	2/12 (16.7%)	5/41 (12.2%)
Ectopic	2/31 (6.3%)	0/13 (0.0%)	0/39 (0.0%)	0/30 (0.0%)	0/12 (0.0%)	2/41 (4.9%)
Loss after observed heart beat	1/31 (3.1%)	2/13 (15.4%)	3/39 (7.7%)	1/30 (3.3%)	1/12 (8.3%)	2/41 (4.9%)
2 <sup>nd</sup> -3 <sup>rd</sup> trimester loss	0/32 (0.0%)	0/13 (0.0%)	2/39 (5.1%)	2/30 (6.7%)	0/12 (0.0%)	2/41 (4.9%)

Ovulation was defined by a serum progesterone level > 5 ng/mL; Conception was defined as any positive serum hCG level; Pregnancy

defined as an intrauterine pregnancy with fetal heart motion as determined by transvaginal ultrasound; and Live Birth defined as delivery of any viable infant.